Agenus Inc
NASDAQ:AGEN
Intrinsic Value
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. [ Read More ]
The intrinsic value of one AGEN stock under the Base Case scenario is 3.11 USD. Compared to the current market price of 5.64 USD, Agenus Inc is Overvalued by 45%.
Valuation Backtest
Agenus Inc
Run backtest to discover the historical profit from buying and selling AGEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Agenus Inc
Current Assets | 112.4m |
Cash & Short-Term Investments | 76.1m |
Receivables | 25.8m |
Other Current Assets | 10.5m |
Non-Current Assets | 201.5m |
PP&E | 163m |
Intangibles | 29.1m |
Other Non-Current Assets | 9.3m |
Current Liabilities | 255.9m |
Accounts Payable | 61.4m |
Accrued Liabilities | 47.9m |
Other Current Liabilities | 146.6m |
Non-Current Liabilities | 218.3m |
Long-Term Debt | 12.8m |
Other Non-Current Liabilities | 205.6m |
Earnings Waterfall
Agenus Inc
Revenue
|
156.3m
USD
|
Cost of Revenue
|
-3.1m
USD
|
Gross Profit
|
153.2m
USD
|
Operating Expenses
|
-313.3m
USD
|
Operating Income
|
-160.1m
USD
|
Other Expenses
|
-85.9m
USD
|
Net Income
|
-246m
USD
|
Free Cash Flow Analysis
Agenus Inc
What is Free Cash Flow?
AGEN Profitability Score
Profitability Due Diligence
Agenus Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Agenus Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
AGEN Solvency Score
Solvency Due Diligence
Agenus Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Agenus Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AGEN Price Targets Summary
Agenus Inc
According to Wall Street analysts, the average 1-year price target for AGEN is 5.61 USD with a low forecast of 3.03 USD and a high forecast of 8.4 USD.
Ownership
AGEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AGEN Price
Agenus Inc
Average Annual Return | 3.87% |
Standard Deviation of Annual Returns | 40.13% |
Max Drawdown | -92% |
Market Capitalization | 2.2B USD |
Shares Outstanding | 418 920 000 |
Percentage of Shares Shorted | 11.48% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.
Contact
IPO
Employees
Officers
The intrinsic value of one AGEN stock under the Base Case scenario is 3.11 USD.
Compared to the current market price of 5.64 USD, Agenus Inc is Overvalued by 45%.